{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:53:34Z","timestamp":1792806814048,"version":"4.5.0"},"reference-count":45,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Wuxi Medicine School of Jiangnan University","award":["FZXK2021011"],"award-info":[{"award-number":["FZXK2021011"]}],"id":[{"id":"https:\/\/ror.org\/04mkzax54","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Wuxi Medicine School of Jiangnan University","award":["2023HYX009"],"award-info":[{"award-number":["2023HYX009"]}],"id":[{"id":"https:\/\/ror.org\/04mkzax54","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Wuxi Health Select Committee","award":["FZXK2021011"],"award-info":[{"award-number":["FZXK2021011"]}]},{"name":"Wuxi Health Select Committee","award":["2023HYX009"],"award-info":[{"award-number":["2023HYX009"]}]},{"name":"Leading Talents in Medical and Health Profession of Wuxi Taihu Lake Talent Plan","award":["FZXK2021011"],"award-info":[{"award-number":["FZXK2021011"]}]},{"name":"Leading Talents in Medical and Health Profession of Wuxi Taihu Lake Talent Plan","award":["2023HYX009"],"award-info":[{"award-number":["2023HYX009"]}]},{"name":"NHC Key Laboratory of Nuclear Technology Medical Transformation","award":["FZXK2021011"],"award-info":[{"award-number":["FZXK2021011"]}]},{"name":"NHC Key Laboratory of Nuclear Technology Medical Transformation","award":["2023HYX009"],"award-info":[{"award-number":["2023HYX009"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tomography"],"abstract":"<jats:p>Objectives: Prostate-specific membrane antigen (PSMA)-targeted radioligands are promising diagnostic tools for the targeted positron emission tomography (PET) imaging of prostate cancer (PCa). In present work, we aimed to develop a novel PSMA tracer to provide an additional option for prostate cancer diagnosis. Methods: Our team designed a new structure of the PSMA tracer and evaluated it with cellular experiments in vitro to preliminarily verify the targeting and specificity of 68Ga-NOTA-GC-PSMA. PET\/CT imaging of PSMA-positive xenograft-bearing models in vivo to further validate the in vivo specificity and targeting of the radiotracer. Pathological tissue sections from prostate cancer patients were compared with pathological immunohistochemistry and pathological tissue staining results by radioautography experiments to assess the targeting-PSMA of 68Ga-NOTA-GC-PSMA on human prostate cancer pathological tissues. Results: The novel tracer showed high hydrophilicity and rapid clearance rate. Specific cell binding and micro-PET imaging experiments showed that 68Ga-NOTA-GC-PSMA displayed a high specific LNCaP tumor cell uptake (1.70% \u00b1 0.13% at 120 min) and tumor-to-muscle (T\/M) and tumor-to-kidney (T\/K) ratio (13.87 \u00b1 11.20 and 0.20 \u00b1 0.08 at 60 min, respectively). Conclusions: The novel tracer 68Ga-NOTA-GC-PSMA is promising radionuclide imaging of PCa.<\/jats:p>","DOI":"10.3390\/tomography11030029","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T12:22:52Z","timestamp":1741350172000},"page":"29","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Preclinical Evaluation of a Novel PSMA-Targeted Agent 68Ga-NOTA-GC-PSMA for Prostate Cancer Imaging"],"prefix":"10.3390","volume":"11","author":[{"given":"Wenjin","family":"Li","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Jiangnan University, No. 1000, Hefeng Road, Wuxi 214000, China"},{"name":"Wuxi School of Medicine, Jiangnan University, No. 1800, Lihu Avenue, Wuxi 214000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihui","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Jiangnan University, No. 1000, Hefeng Road, Wuxi 214000, China"},{"name":"Wuxi School of Medicine, Jiangnan University, No. 1800, Lihu Avenue, Wuxi 214000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8279-6051","authenticated-orcid":false,"given":"Yuqi","family":"Hua","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Jiangnan University, No. 1000, Hefeng Road, Wuxi 214000, China"},{"name":"Wuxi School of Medicine, Jiangnan University, No. 1800, Lihu Avenue, Wuxi 214000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoling","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Jiangnan University, No. 1000, Hefeng Road, Wuxi 214000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Jiangnan University, No. 1000, Hefeng Road, Wuxi 214000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Jiangnan University, No. 1000, Hefeng Road, Wuxi 214000, China"},{"name":"Wuxi School of Medicine, Jiangnan University, No. 1800, Lihu Avenue, Wuxi 214000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitian","family":"Fu","sequence":"additional","affiliation":[{"name":"Wuxi School of Medicine, Jiangnan University, No. 1800, Lihu Avenue, Wuxi 214000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9752-8551","authenticated-orcid":false,"given":"Chunjing","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Jiangnan University, No. 1000, Hefeng Road, Wuxi 214000, China"},{"name":"Wuxi School of Medicine, Jiangnan University, No. 1800, Lihu Avenue, Wuxi 214000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA-A Cancer J. Clin."},{"key":"ref_2","unstructured":"(2025, February 25). Survival Rates for Prostate Cancer. Available online: https:\/\/www.cancer.org\/cancer\/types\/prostate-cancer\/detection-diagnosis-staging\/survival-rates.html."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s13402-014-0194-4","article-title":"Molecular imaging of targeted therapies with positron emission tomography: The visualization of personalized cancer care","volume":"38","author":"Mammatas","year":"2015","journal-title":"Cell. Oncol."},{"key":"ref_4","first-page":"18N","article-title":"A Definition of Molecular Imaging","volume":"48","author":"Mankoff","year":"2007","journal-title":"J. Nucl. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3322\/caac.21713","article-title":"Molecular imaging in oncology: Current impact and future directions","volume":"72","author":"Rowe","year":"2022","journal-title":"CA-A Cancer J. Clin."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"6502","DOI":"10.1007\/s00330-023-09619-8","article-title":"PET radiotracers for whole-body in vivo molecular imaging of prostatic neuroendocrine malignancies","volume":"33","author":"Cohen","year":"2023","journal-title":"Eur. Radiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"6108","DOI":"10.1021\/jm400823w","article-title":"Effect of Chelators on the Pharmacokinetics of 99mTc-Labeled Imaging Agents for the Prostate-Specific Membrane Antigen (PSMA)","volume":"56","author":"Pullambhatla","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/nrclinonc.2012.188","article-title":"Is there still a role for SPECT\u2013CT in oncology in the PET\u2013CT era?","volume":"9","author":"Hicks","year":"2012","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Cri\u0219an, G., Moldovean-Cioroianu, N.S., Timaru, D.-G., Andrie\u0219, G., C\u0103inap, C., and Chi\u0219, V. (2022). Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23095023"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Jones, W., Griffiths, K., Barata, P.C., and Paller, C.J. (2020). PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy. Cancers, 12.","DOI":"10.3390\/cancers12061367"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Hennrich, U., and Eder, M. (2021). [68Ga]Ga-PSMA-11: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer. Pharmaceuticals, 14.","DOI":"10.3390\/ph14080713"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1007\/s00259-018-4037-9","article-title":"68Ga-PSMA-617 PET\/CT: A promising new technique for predicting risk stratification and metastatic risk of prostate cancer patients","volume":"45","author":"Liu","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.2967\/jnumed.115.161299","article-title":"The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET\/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions","volume":"56","author":"Hetzheim","year":"2015","journal-title":"J. Nucl. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4103\/ijnm.ijnm_8_24","article-title":"An Analysis of the Diagnostic Performance of Tc-99m PSMA SSPECT\/CT in Biochemically Recurrent Prostate Cancer Compared with Ga-68 PSMA PET\/CT: A Single-center, Prospective Study","volume":"39","author":"Ora","year":"2024","journal-title":"Indian J. Nucl. Med."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Brunello, S., Salvarese, N., Carpanese, D., Gobbi, C., Melendez-Alafort, L., and Bolzati, C. (2022). A Review on the Current State and Future Perspectives of [99mTc]Tc-Housed PSMA-i in Prostate Cancer. Molecules, 27.","DOI":"10.3390\/molecules27092617"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.2967\/jnumed.122.265252","article-title":"Delayed Imaging Improves Lesion Detectability in [99mTc]Tc-PSMA-I&S SPECT\/CT in Recurrent Prostate Cancer","volume":"64","author":"Berliner","year":"2023","journal-title":"J. Nucl. Med."},{"key":"ref_17","first-page":"1","article-title":"Direct comparison of 99mTc-PSMA SPECT\/CT and 68Ga-PSMA PET\/CT in patients with prostate cancer","volume":"8","author":"Albalooshi","year":"2020","journal-title":"Asia Ocean. J. Nucl. Med. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Kristiansson, A., Vilhelmsson Timmermand, O., Altai, M., Strand, J., Strand, S.E., \u00c5kerstr\u00f6m, B., and \u00d6rbom, A. (2022). Hematological Toxicity in Mice after High Activity Injections of (177)Lu-PSMA-617. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14040731"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Lin, Z., Li, T., Wei, Y., Yu, M., Ye, L., Cai, Y., Yang, S., Zhang, Y., and Shi, Y. (2022). Head-to-head comparison of 99mTc-PSMA and 99mTc-MDP SPECT\/CT in diagnosing prostate cancer bone metastasis: A prospective, comparative imaging trial. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-20280-x"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Vargas-Ahumada, J.E., Gonz\u00e1lez-Rueda, S.D., Sinisterra-Sol\u00eds, F.A., Casanova-Trivi\u00f1o, P., Pital\u00faa-Cort\u00e9s, Q., Soldevilla-Gallardo, I., Scavuzzo, A., Jimenez-R\u00edos, M.A., and Garc\u00eda-P\u00e9rez, F.O. (2023). Diagnostic Performance of 99mTc-iPSMA SPECT\/CT in the Initial Staging of Patients with Unfavorable Intermediate-, High-, and Very High-Risk Prostate Cancer: A Comparative Analysis with 18F-PSMA-1007 PET\/CT. Cancers, 15.","DOI":"10.3390\/cancers15245824"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Wang, Q., Ketteler, S., Bagheri, S., Ebrahimifard, A., Luster, M., Librizzi, D., and Yousefi, B.H. (2024). Diagnostic efficacy of [99mTc]Tc-PSMA SPECT\/CT for prostate cancer: A meta-analysis. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-12734-4"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1021\/bc200279b","article-title":"68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging","volume":"23","author":"Eder","year":"2012","journal-title":"Bioconj. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"914","DOI":"10.2967\/jnumed.114.147413","article-title":"Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer","volume":"56","author":"Kratochwil","year":"2015","journal-title":"J. Nucl. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1021\/acs.bioconjchem.7b00458","article-title":"Improving the Imaging Contrast of 68Ga-PSMA-11 by Targeted Linker Design: Charged Spacer Moieties Enhance the Pharmacokinetic Properties","volume":"28","author":"Baranski","year":"2017","journal-title":"Bioconj. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","article-title":"PSMA PET\/CT: Joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0","volume":"50","author":"Fendler","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrurol.2016.26","article-title":"Current use of PSMA\u2013PET in prostate cancer management","volume":"13","author":"Maurer","year":"2016","journal-title":"Nat. Rev. Urol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1002\/1878-0261.13071","article-title":"Emerging methods for prostate cancer imaging: Evaluating cancer structure and metabolic alterations more clearly","volume":"15","author":"Retter","year":"2021","journal-title":"Mol. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer\u20142020 update. Part 1: Screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2967\/jnumed.120.257238","article-title":"Current and Emerging Clinical Applications of PSMA PET Diagnostic Imaging for Prostate Cancer","volume":"62","author":"Farolfi","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/13543776.2021.1878145","article-title":"Inhibitors of prostate-specific membrane antigen in the diagnosis and therapy of metastatic prostate cancer\u2013a review of patent literature","volume":"31","author":"Ha","year":"2021","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/ajoc.201900329","article-title":"Prostate-Specific Membrane Antigen (PSMA)-Targeted Radionuclide Probes for Imaging and Therapy of Prostate Cancer","volume":"8","author":"Kwon","year":"2019","journal-title":"Asian J. Org. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Mosayebnia, M., Hajimahdi, Z., Beiki, D., Rezaeianpour, M., Hajiramezanali, M., Geramifar, P., sabzevari, O., Amini, M., Hatamabadi, D., and Shahhosseini, S. (2020). Design, synthesis, radiolabeling and biological evaluation of new urea-based peptides targeting prostate specific membrane antigen. Bioorg. Chem., 99.","DOI":"10.1016\/j.bioorg.2020.103743"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"El Fakiri, M., Geis, N.M., Ayada, N., Eder, M., and Eder, A.C. (2021). PSMA-Targeting Radiopharmaceuticals for Prostate Cancer Therapy: Recent Developments and Future Perspectives. Cancers, 13.","DOI":"10.3390\/cancers13163967"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"17s","DOI":"10.2967\/jnumed.116.186775","article-title":"Glu-Ureido-Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers","volume":"58","author":"Kopka","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1021\/acs.jmedchem.5b01210","article-title":"Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors","volume":"59","author":"Klika","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Kim, S.B., Song, I.H., Song, Y.S., Lee, B.C., Gupta, A., Lee, J.S., Park, H.S., and Kim, S.E. (2021). Biodistribution and internal radiation dosimetry of a companion diagnostic radiopharmaceutical, [68Ga]PSMA-11, in subcutaneous prostate cancer xenograft model mice. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-94684-6"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"6889","DOI":"10.1021\/acs.jmedchem.3c00309","article-title":"Design and Characterization of Squaramic Acid-Based Prostate-Specific Membrane Antigen Inhibitors for Prostate Cancer","volume":"66","author":"Wang","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.juro.2015.12.025","article-title":"Diagnostic efficacy of 68gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer","volume":"195","author":"Maurer","year":"2016","journal-title":"J. Urol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1021\/jm200065e","article-title":"Use of a HEHEHE purification tag instead of a hexahistidine tag improves biodistribution of affibody molecules site-specifically labeled with 99mTc, 111In, and 125I","volume":"54","author":"Orlova","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1007\/s00259-016-3437-y","article-title":"Synthesis and preclinical evaluation of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand","volume":"43","author":"Boschi","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/pros.22789","article-title":"Improving the biodistribution of PSMA-targeting tracers with a highly negatively charged linker","volume":"74","author":"Huang","year":"2014","journal-title":"Prostate"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1021\/acs.molpharmaceut.8b00499","article-title":"Effects of Linker Modification on Tumor-to-Kidney Contrast of 68Ga-Labeled PSMA-Targeted Imaging Probes","volume":"15","author":"Kuo","year":"2018","journal-title":"Mol. Pharm."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1021\/acs.bioconjchem.5b00687","article-title":"Novel Bispecific PSMA\/GRPr Targeting Radioligands with Optimized Pharmacokinetics for Improved PET Imaging of Prostate Cancer","volume":"27","author":"Liolios","year":"2016","journal-title":"Bioconj. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1021\/bc970047i","article-title":"Simplified preformed chelate protein radiolabeling with technetium-99m mercaptoacetamidoadipoylglycylglycine (N3S-adipate)","volume":"9","author":"Kasina","year":"1998","journal-title":"Bioconj. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.2174\/1389557521666210521114024","article-title":"A Review of 99mTc-labeled Tumor Metabolic Imaging Agents","volume":"22","author":"Li","year":"2022","journal-title":"Mini-Rev. Med. Chem."}],"container-title":["Tomography"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2379-139X\/11\/3\/29\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:49:13Z","timestamp":1760028553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2379-139X\/11\/3\/29"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,7]]},"references-count":45,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["tomography11030029"],"URL":"https:\/\/doi.org\/10.3390\/tomography11030029","relation":{},"ISSN":["2379-139X"],"issn-type":[{"value":"2379-139X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,7]]}}}